14 completed, 3 not yet recruiting, 3 terminated, 3 withdrawn. 29 Phase 2, 5 Phase 3, 2 Phase 1.
Follow Community-Acquired Pneumonia: new trials by email Literature Review of Community-Acquired Pneumonia trials Research Report on Community-Acquired Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia Inhaled levofloxacin, Standard-of-care / Usual care - Community-acquired Pneumonia, CAP | Phase 2 / Phase 3 | Active not recruiting | Copenhagen Respiratory Research | 460 | 2026-10-08 | 2026-11-05 |
| Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia NRICM102, Placebo, Intravenous Antibiotic - Mild to Moderate, Community-Acquired Pneumonia (CAP) | Phase 2 | Not yet recruiting | National Research Institute of Chinese Medicine, Ministry of Health and Welfare | 150 | 2026-06-01 | 2026-05-13 |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced by Community-Acquired Pneumonia Methylprednisolone - Acute Respiratory Failure, Community-Acquired Pneumonia | Phase 1 / Phase 2 | Not yet recruiting | Qingyuan Zhan | 500 | 2026-02-01 | 2026-01-22 |
| Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal) Low dose steroids, Moderate dose steroids, Saline (0.9% NaCl) - Severe Community-acquired Pneumonia (sCAP) | Phase 2 / Phase 3 | Not yet recruiting | Qingyuan Zhan | 1500 | 2025-09-08 | 2025-09-03 |
| Local Antibiotic Delivery for Community Acquired Pneumonia Levofloxacin, Placebo - Community Acquired Pneumonia (CAP) | Phase 2 / Phase 3 | Active not recruiting | Copenhagen Respiratory Research | 36 | 2025-03-04 | 2026-11-06 |
| Efficacy and Safety of SR1375 in Adult Patients With CAP SR1375 capsule 3mg+regular treatments, SR1375 capsule 1mg+regular treatments, SR1375 capsule 0.3mg+regular treatments - Community-acquired Pneumonia | Phase 2 | Recruiting | Shanghai SIMR Biotechnology Co., Ltd. | 240 | 2024-09-10 | 2025-07-09 |
| CX-4945 in Viral Community Acquired Pneumonia CX-4945 (SARS-CoV-2 domain), Placebo (SARS-CoV-2 domain), CX-4945 (Influenza virus domain) - Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia | Phase 2 | Terminated | Senhwa Biosciences, Inc. | 45 | 2024-03-20 | 2026-01-08 |
| Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. AON-D21, Placebo - Community-acquired Pneumonia | Phase 2 | Completed | Aptarion Biotech AG | 150 | 2024-02-02 | 2026-03-18 |
| A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS Augmentin ES - Infections, Bacterial | Phase 2 | Withdrawn | GlaxoSmithKline | 2023-10-14 | 2025-03-28 | |
| Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia Anakinra Prefilled Syringe, Placebo - Community-acquired Pneumonia, Hospital-acquired Pneumonia | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 60 | 2023-03-06 | 2024-07-31 |
| Corticosteroids in Community Acquired Pneumonia Prednisone, Placebo - Community-acquired Pneumonia, Cognition Disorder | Phase 2 | Withdrawn | Vanderbilt University Medical Center | 2020-12-01 | 2023-02-08 | |
| A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients Allocetra-OTS, Placebo - Sepsis, Community-acquired Pneumonia | Phase 2 | Completed | Enlivex Therapeutics Ltd. | 148 | 2020-11-30 | 2025-08-19 |
| Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19 Trimodulin, Placebo (human albumin 1%) - Covid19 | Phase 2 | Completed | Biotest | 166 | 2020-10-06 | 2023-01-10 |
| A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP Recombinant Human Plasma Gelsolin, Normal Saline Placebo - Community-acquired Pneumonia | Phase 1 / Phase 2 | Completed | BioAegis Therapeutics Inc. | 33 | 2018-08-28 | 2020-01-27 |
| Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia. Amoxicillin - Community-acquired Pneumonia | Phase 2 / Phase 3 | Recruiting | St. Justine's Hospital | 1370 | 2017-06-11 | 2026-11-18 |
| Ticagrelor in Severe Community Acquired Pneumonia Ticagrelor, Placebo - Community Acquired Pneumonia, Severe | Phase 2 | Terminated | Gordon Bernard | 25 | 2014-08-01 | 2017-12-11 |
| Short Duration Treatment of Non-severe Community Acquired Pneumonia Chest X-ray, blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry, Augmentin - Community Acquired Pneumonia | Phase 2 | Unknown | Versailles Hospital | 310 | 2013-11-01 | 2017-08-14 |
| Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate - Infections, Community Acquired Pneumonia | Phase 2 / Phase 3 | Completed | Forest Laboratories | 161 | 2012-09-01 | 2015-01-13 |
| Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP BT086, 1% Human Albumin infusion - Community Acquired Pneumonia | Phase 2 | Completed | Biotest | 160 | 2011-08-01 | 2015-07-29 |
Showing 20 of 29. Sign in to see all of them.
Pneumonia (6) · Sepsis (4) · COVID-19 (2) · Respiratory Distress Syndrome (2) · Asthma (1) · Bacterial Infections (1) · Cholecystitis, Acute (1) · Cognition Disorders (1) · Healthcare-Associated Pneumonia (1) · Infections (1) · Influenza, Human (1) · Intraabdominal Infections (1) · Lymphoma, Follicular (1) · Lymphopenia (1)
Community-Acquired Infections (29) · Respiratory Tract Diseases (29) · Respiratory Tract Infections (29) · Infections (28) · Pneumonia (23) · Lung Diseases (11) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Inflammation (4) · Systemic Inflammatory Response Syndrome (4) · Immune System Diseases (3) · Bacterial Infections and Mycoses (2) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Disease Attributes (2)
Amoxicillin-Potassium Clavulanate Combination (3) · Levofloxacin (3) · Cell Count (2) · ALT-803 (1) · Amoxicillin (1) · Blood Specimen Collection (1) · C-Reactive Protein (1) · Ceftaroline (1) · Ceftriaxone (1) · Duration of Therapy (1) · EDP 420 (1) · Ertapenem (1) · Interleukin 1 Receptor Antagonist Protein (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1)
Biotest (2) · Copenhagen Respiratory Research (2) · Qingyuan Zhan (2) · TaiGen Biotechnology Co., Ltd. (2) · Aptarion Biotech AG (1) · BioAegis Therapeutics Inc. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Enanta Pharmaceuticals, Inc (1) · Enlivex Therapeutics Ltd. (1) · Forest Laboratories (1) · GlaxoSmithKline (1) · Gordon Bernard (1) · Hellenic Institute for the Study of Sepsis (1) · IASO Pharma Inc. (1) · ICOS Corporation (1)
United States (8) · Spain (5) · France (4) · Belgium (3) · China (3) · Germany (3) · Taiwan (3) · Brazil (2) · Canada (2) · Denmark (2) · Georgia (2) · Greece (2) · Poland (2) · Russia (2) · South Africa (2)
AJ Bester, Doctor (1) · Antoni Torres, MD (1) · CT de Villiers, Doctor (1) · DJ Jansen van Rensburg, Doctor (1) · E van Nieuwenhuizen, Doctor (1) · Evangelos Giamarellos-Bourboulis, MD, PhD (1) · G Nieuwoudt, Doctor (1)
PMID 26748734, PMID 27093162, PMID 29632995, PMID 32690640, PMID 33351126, PMID 33773631, PMID 38734138, PMID 39138518, PMID 41552367